ills have served biopharma pretty well over the years. Easy to design and cheap to produce, the so-called small-molecule therapies that fit in a capsule have made billions of dollars for their inventors and treated millions of patients in the process.

Now, however, as yesteryear’s swallowable blockbusters go generic, the industry is running into diseases for which pills can find no quarter.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Boston Globe – This is a huge “bait and switch”! I pay for my subscription to the Globe and when I click on the first article in the business section, you tell me you want more money!?! This leaves a really bad taste in my mouth.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.